Francis Armendariz
Psychiatry · Lawton, OKNPI 1265442693
Payments from drug & device makers
Across 175 payments — averaging $10.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$604
- Otsuka America Pharmaceutical, Inc.$542
- Lundbeck LLC$185
- Supernus Pharmaceuticals, Inc.$139
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$124
- Johnson & Johnson$51
- plus $224 from 8 others
What the payments were for
- Food & beverage$1,870100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $604 |
| Otsuka America Pharmaceutical, Inc. | 43 | $542 |
| Lundbeck LLC | 12 | $185 |
| Supernus Pharmaceuticals, Inc. | 7 | $139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $124 |
| Johnson & Johnson | 3 | $51 |
| Corium, LLC | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Brainsway USA Inc | 1 | $40 |
| Sage Therapeutics, LLC | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
How this compares
$1,870 in reported general payments places this provider in the 75th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 175 | $310,854 |
| VraylarCariprazine Hcl | 212 | $306,168 |
| IngrezzaValbenazine Tosylate | 24 | $193,823 |
| TrintellixVortioxetine Hydrobromide | 54 | $39,196 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $19,769 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $15,803 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 155 | $5,614 |
| BelsomraSuvorexant | 12 | $5,025 |
| Methylphenidate ErMethylphenidate Hcl | 68 | $4,181 |
| Clonazepam | 321 | $3,491 |
| Trazodone Hcl | 300 | $3,328 |
| Sertraline Hcl | 205 | $3,278 |
| Quetiapine Fumarate | 236 | $2,718 |
| Ziprasidone Hcl | 55 | $2,519 |
| Methylphenidate Hcl | 97 | $2,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $542 | $310,854175 claims |
| AbbVieVraylar | $604 | $306,168212 claims |
| Axsome Therapeutics, Inc.Auvelity | $16 | $19,76915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Lawton
- Louise ThurmanOklahoma City$6.2M
- Veronique SebastianOklahoma City$3.8M
- Marvin PeytonOklahoma City$3.2M
- Sarah LandTulsa$2.8M
- Robert MortonAda$1.9M
- Willis HollowayOklahoma City$1.4M
- Courtney NixonOklahoma City$1.2M
- Surinder RandhawaOklahoma City$142K
- Adonis Al BotrosOklahoma City$73K
- Ondria GleasonTulsa$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.